<DOC>
	<DOCNO>NCT02332642</DOCNO>
	<brief_summary>This pilot clinical trial aim evaluate immuno-modulating effect palliative treatment specifically dosed standard chemotherapeutics patient metastatic melanoma ( AJCC stage IV ) assess myeloid-derived suppressor cell ' ( MDSCs ) count activity .</brief_summary>
	<brief_title>Immuno-monitoring Patients With Metastatic Melanoma ( AJCC Stadium IV ) Under Chemotherapy</brief_title>
	<detailed_description />
	<criteria>histologically define metastatic melanoma patient ( AJCC stage IV ) age 18 80 year least one prior systemic antimelanoma therapy ; BRAFV600 positive , least one prior BRAFi therapy therapynaive patient contraindication ( specific ) systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>